An Open-label Phase 3 Trial to Assess the Safety and Immunogenicity of a Live-attenuated Chikungunya Virus Vaccine (VLA1553) in Moderately Immunocompromised Adult Participants Infected with Human Immunodeficiency Virus
Latest Information Update: 04 Dec 2024
At a glance
- Drugs VLA 1553 (Primary)
- Indications Chikungunya virus infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Valneva
Most Recent Events
- 02 Dec 2024 Status changed to withdrawn prior to enrolment due to challenges related to recruitment
- 23 Apr 2024 Planned End Date changed from 1 Jan 2025 to 1 Sep 2025.
- 23 Apr 2024 Status changed from not yet recruiting to recruiting.